Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Provider Statement: This continuing medical education activity is provided by 
.
Support Statement: This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Target Audience: The intended audience for the activity is hematologists and other health care professionals involved in the management of patients with sickle cell disease.
Learning Objectives: Upon successful completion of this activity, participants should be better able to:
- Evaluate the latest advances in treatment options for patients with SCD and how patients may benefit.
- Examine the latest understanding regarding SCD phenotypes and implications for treatment selection and sequencing.
- Describe how emerging SCD treatments may impact current standard of care and the role that hematologists may play in patient education.
Activity Chair:
Kenneth I. Ataga, MD
Professor
Department of Medicine
Division of Hematology and Oncology
Director, Center for Sickle Cell Disease
University of Tennessee Health Science Center
Memphis, TN
Faculty:
Jo Howard, MB BChir
Consultant and Lead Hematologist
Guy’s and St Thomas’ NHS Foundation Trust
London, UK
Julie Kanter, MD
Associate Professor
Division of Hematology and Oncology
Director, Adult Sickle Cell Clinic
University of Alabama School of Medicine
Birmingham, AL
Abdullah Kutlar, MD
Professor of Medicine
Director, Center for Blood Disorders
Department of Medicine
Medical College of Georgia at Augusta University
Augusta, GA
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, March 24, 2020, through March 23, 2021.
How to Participate in This Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.
Activity Chair and Faculty report the following relationship(s):
Kenneth I. Ataga, MD
Advisory Board: Editas Medicine, Emmaus Life Sciences, Global Blood Therapeutics, Novartis
Jo Howard, MB BChir
Consulting Fee: Global Blood Therapeutics, Imara
Contracted Research: Global Blood Therapeutics
Travel Grant: Imara, Resonance Health
Julie Kanter, MD
Consulting Fee: Editas, GLG, Guidepoint Global, Imara, Modus Therapeutics, Novartis, Pfizer, Sangamo, Terumo
Non-CME Services Fees: Medscape, PeerVoice, Rockpointe
Contracted Research: Bluebird Bio, Cyclerion, Global Blood Therapeutics, Imara, Novartis, Shire
Abdullah Kutlar, MD
Consulting Fee: Novartis
Reviewer reports the following relationship(s):
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com